Radiopharm Theranostics’ (ASX: RAD) lung cancer trial to have 2nd Australian site in Perth

December 27, 2023 01:05 PM AEDT | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp


  • Hollywood Private Hospital in Perth has given Ethics Committee approval.
  • With this development, Hollowood Private Hospital becomes 2nd Australian site for RAD 204 Phase 1 trial.
  • Recruitment for the trial would commence at Princess Alexandra Hospital in Brisbane.
  • The trial is designed for patients with PD-L1-positive non-small cell lung cancer (NSCLC).

Radiopharm Theranostics Limited (ASX: RAD) would be opening a second site for its lung cancer trial.

As per the latest company update, Hollywood Private Hospital in Perth, Western Australia, has granted Human Research Ethics Committee (HREC) approval. With this development, Hollywood Private Hospital will become the second site in Australia for RAD 204 Phase 1 therapeutic study, which is focused on PD-L1-positive non-small cell lung cancer (NSCLC).

The addition of Perth site has resulted in widening of the geographic availability of the trial, and the recruitment is anticipated to advance accordingly. GenesisCare, a major oncology provider, is supporting the trial.

About the RAD 204 Phase 1 therapeutic study

The title of the study is –

Data source: Company update

It is the first-in-human dose escalation study of 177Lu-RAD 204, which aims at examining the efficacy and safety of 177Lu-RAD 204 in individuals with advanced NSCLC.

NSCLC is the most common type of lung cancer. Data from the American Cancer Society indicates that by the end of 2023, nearly 300,000 new lung cancer cases are estimated to be reported in the US, and 81% of this are expected to be diagnosed with NSCLC.

The trial is expected to open on 4 January 2024 at Princess Alexandra Hospital in Brisbane. In January 2024, the first patient is expected to be dosed.

This is what CEO and MD of RAD, Riccardo Canevari, commented on the latest development -

RAD shares traded at AU$0.071 midday on 27 December 2023.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.